Screener
Sionna Therapeutics SION Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Sionna Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Sionna Therapeutics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 7:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033876
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from initial public offering, net of underwriter discounts, commissions and offering costs paid during the period | — | 202,389 |
| Payment of deferred offering costs | (320) | — |
| Exercise of common stock options | 2,213 | — |
| Net cash provided by financing activities | 1,893 | 202,389 |
| Net increase in cash, cash equivalents and restricted cash | 4,873 | 44,907 |
| Cash, cash equivalents and restricted cash at beginning of period | 59,414 | 38,750 |
| Cash, cash equivalents and restricted cash at end of period | $64,287 | $83,657 |
| Supplemental disclosure of non-cash investing and financing activities: |
Item 1. Financial Statements
FAQ
- What is Sionna Therapeutics's financing cash flow?
- Sionna Therapeutics (SION) reported financing cash flow of $1.89M in Q1 2026.
- How has Sionna Therapeutics's financing cash flow changed year-over-year?
- Sionna Therapeutics's financing cash flow decreased by 99.1% year-over-year, from $202.39M to $1.89M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Sionna Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude